Cumate-inducible models of MYC-driven neuroblastoma identify mitoribosomal synthetic lethality as a precision oncology vulnerability in MYC(N)-amplified tumors

Mitoribosomal synthetic lethality is a vulnerability in MYC(N)-amplified neuroblastoma, with MYC activation sensitizing cells to mitochondrial ribosome inhibitors.

• Why it matters: Understanding specific dependencies in MYC-driven cancers can lead to targeted therapies, but existing gene regulation systems often interfere with mitochondrial function, complicating research.
• What they did: Researchers developed novel cumate-inducible neuroblastoma models to precisely control MYC/MYCN expression without off-target effects, validating the synthetic lethality with mitochondrial ribosome inhibitors in cell lines and patient samples.
• The result: Findings demonstrate that MYC(N) activation makes neuroblastoma cells vulnerable to mitoribosomal inhibitors like doxycycline, enabling a promising, targeted therapeutic approach for MYC-driven neuroblastoma.